HIV-1 entry inhibitors: Evading the issue

被引：84

作者：

Michael, NL

Moore, JP

机构：

[1] Walter Reed Army Inst Res, Rockville, MD 20850 USA

[2] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA

来源：

NATURE MEDICINE | 1999年 / 5卷 / 07期

关键词：

D O I：

10.1038/10462

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

HIV-1 entry into cells is an attractive target for new antiviral agents. But will inhibitors aimed at the CCR5 co-receptor force HIV-1 to evolve more virulent forms?

引用

页码：740 / 742

页数：3

共 24 条

[1] A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity [J].

Baba, M ;

Nishimura, O ;

Kanzaki, N ;

Okamoto, M ;

Sawada, H ;

Iizawa, Y ;

Shiraishi, M ;

Aramaki, Y ;

Okonogi, K ;

Ogawa, Y ;

Meguro, K ;

Fujino, M .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) :5698-5703

[2]

Berger EA, 1997, AIDS, V11, pS3

[3]

BERGER EA, 1999, AIDS, V391

[4]

BERGER EA, 1999, NATURE, V391

[5] The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes [J].

Bleul, CC ;

Wu, LJ ;

Hoxie, JA ;

Springer, TA ;

Mackay, CR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (05) :1925-1930

[6] The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates [J].

Choe, H ;

Farzan, M ;

Sun, Y ;

Sullivan, N ;

Rollins, B ;

Ponath, PD ;

Wu, LJ ;

Mackay, CR ;

LaRosa, G ;

Newman, W ;

Gerard, N ;

Gerard, C ;

Sodroski, J .

CELL, 1996, 85 (07) :1135-1148

[7] SYNCYTIUM-INDUCING (SI) PHENOTYPE SUPPRESSION AT SEROCONVERSION AFTER INTRAMUSCULAR INOCULATION OF A NON-SYNCYTIUM-INDUCING/SI PHENOTYPICALLY MIXED HUMAN-IMMUNODEFICIENCY-VIRUS POPULATION [J].

CORNELISSEN, M ;

MULDERKAMPINGA, G ;

VEENSTRA, J ;

ZORGDRAGER, F ;

KUIKEN, C ;

HARTMAN, S ;

DEKKER, J ;

VANDERHOEK, L ;

SOL, C ;

COUTINHO, R ;

GOUDSMIT, J .

JOURNAL OF VIROLOGY, 1995, 69 (03) :1810-1818

[8] Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene [J].

Dean, M ;

Carrington, M ;

Winkler, C ;

Huttley, GA ;

Smith, MW ;

Allikmets, R ;

Goedert, JJ ;

Buchbinder, SP ;

Vittinghoff, E ;

Gomperts, E ;

Donfield, S ;

Vlahov, D ;

Kaslow, R ;

Saah, A ;

Rinaldo, C ;

Detels, R ;

OBrien, SJ .

SCIENCE, 1996, 273 (5283) :1856-1862

[9] AMD310, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor [J].

Donzella, GA ;

Schols, D ;

Lin, SW ;

Esté, JA ;

Nagashima, KA ;

Maddon, PJ ;

Allaway, GP ;

Sakmar, TP ;

Henson, G ;

De Clercq, E ;

Moore, JP .

NATURE MEDICINE, 1998, 4 (01) :72-77

[10] Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy [J].

Finzi, D ;

Blankson, J ;

Siliciano, JD ;

Margolick, JB ;

Chadwick, K ;

Pierson, T ;

Smith, K ;

Lisziewicz, J ;

Lori, F ;

Flexner, C ;

Quinn, TC ;

Chaisson, RE ;

Rosenberg, E ;

Walker, B ;

Gange, S ;

Gallant, J ;

Siliciano, RF .

NATURE MEDICINE, 1999, 5 (05) :512-517

← 1 2 3 →